Tango Therapeutics, Inc. Cash and Cash Equivalents
Tango Therapeutics, Inc. (TNGX) had Cash and Cash Equivalents of $345.56 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $345.56M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $157.83M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $112.28M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $58.34M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $345.56M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $157.83M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $112.28M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $58.34M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $39.27M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $58.43M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $69.53M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $53.15M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $51.57M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $61.16M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $66.39M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $58.53M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $66.05M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $57.25M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $59.97M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $100.31M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $104.58M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $99.91M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $142.75M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $204.97M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $582.94K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.26M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $28.38M 10-K · filed 2022-03-28 | $1.31M 10-K · filed 2021-03-31 |
| 2020-09-30 | $1.55M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $24.99K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |